A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia"

Affiliations

¹ AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
² Johns Hopkins University School of Medicine, University in Baltimore, Baltimore, Maryland.
³ Department of Renal Medicine, King's College Hospital, London, United Kingdom.
⁴ Auerbach Hematology and Oncology, Baltimore, Maryland.
⁵ Stanford University School of Medicine, Stanford, California.

Free article

Comment

William E Strauss et al. Am J Hematol. 2018 Sep.

Free article

. 2018 Sep;93(9):E232-E233.

doi: 10.1002/ajh.25200. Epub 2018 Aug 6.

¹ AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
² Johns Hopkins University School of Medicine, University in Baltimore, Baltimore, Maryland.
³ Department of Renal Medicine, King's College Hospital, London, United Kingdom.
⁴ Auerbach Hematology and Oncology, Baltimore, Maryland.
⁵ Stanford University School of Medicine, Stanford, California.

No abstract available

Comment on

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, Chertow GM, Krop JS. Adkinson NF, et al. Am J Hematol. 2018 May;93(5):683-690. doi: 10.1002/ajh.25060. Epub 2018 Feb 24. Am J Hematol. 2018. PMID: 29417614 Free PMC article. Clinical Trial.
A comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia.
Mundy LM, Wohlfeil S. Mundy LM, et al. Am J Hematol. 2018 Sep;93(9):E231-E232. doi: 10.1002/ajh.25204. Epub 2018 Aug 31. Am J Hematol. 2018. PMID: 29981266 No abstract available.